ClinicalTrials.gg
RecruitingNCT04625907FaR-RMSUpdated May 23, 2024

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

A Phase 1/2 interventional study of Irinotecan and Actinomycin D in Rhabdomyosarcoma, sponsored by University of Birmingham. Recruiting at 128 sites in 20 countries. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by University of Birmingham · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,672
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing irinotecan in Rhabdomyosarcoma — 4 open to participants now, 6 under way, none of them phase 3. Irinotecan · Rhabdomyosarcoma.

Planned enrollment
Largest of 14
1,672 · median 102
Started
2020
the only one that year
Phase 1/2
2 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies testing irinotecan in Rhabdomyosarcoma, this one has the largest planned enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 12th registered.

Rhabdomyosarcoma

238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.

Browse Rhabdomyosarcoma studies →

Open to participants now

4 of the 14 studies testing irinotecan in Rhabdomyosarcoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing irinotecan in Rhabdomyosarcoma, or all of them as a file.
02

Study summary

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Read the detailed description

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS). It is a multi-arm, multi-stage format, involving several different trial questions. FaR-RMS is intended to be a rolling programme of research with new treatment arms being introduced dependant on emerging data and innovation. This study has multiple aims. It aims to evaluate the impact of new agent regimens in both newly diagnosed and relapsed RMS; whether changing the duration of maintenance therapy affects outcome; and whether changes to dose, extent (in metastatic disease) and timing of radiotherapy improve outcome and quality of life. In addition the study will evaluate risk stratification through the use of PAX-FOXO1 fusion gene status instead of histological subtyping and explore the use of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction chemotherapy.

Newly diagnosed patients should, where possible, be entered into the FaR-RMS study at the time of first diagnosis prior to receiving any chemotherapy. However, patients can enter at the point of radiotherapy or maintenance, and those with relapsed disease can enter the study even if not previously entered at initial diagnosis. Patients may be entered into more than one randomisation/registration, dependant on patient risk group and disease status.

03

Conditions studied

  • Rhabdomyosarcoma

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for study entry - Mandatory at first point of study entry

  1. confirmed diagnosis of RMS (except pleomorphic RMS)
  2. Written from the patient and/or the parent/legal guardian

Phase 1b Dose Finding - IRIVA Inclusion

  1. Entered in to the FaR-RMS study at diagnosis
  2. Very High Risk disease
  3. Age >12 months and ≤25 years
  4. No prior treatment for RMS other than surgery
  5. Medically fit to receive treatment
  6. Adequate hepatic function:

    1. Total ≤ 1.5 times (ULN) for age, unless the patient is known to have Gilbert's syndrome
    2. or AST \< 2.5 X ULN for age
  7. ≥1.0x 109/L
  8. ≥ 80 x 109/L
  9. Adequate renal function: estimated or measured ≥60 ml/min/1.73 m2
  10. Documented negative pregnancy test for female patients of
  11. Patient agrees to use during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  12. Written informed consent from the patient and/or the parent/legal guardian

Exclusion

  1. Weight \<10kg
  2. Active > grade 2 diarrhoea
  3. Prior allo- or Stem Cell Transplant
  4. Uncontrolled inter-current illness or active infection
  5. Pre-existing medical condition precluding treatment
  6. Urinary outflow obstruction that cannot be relieved prior to starting treatment
  7. Active inflammation of the urinary bladder (cystitis)
  8. Known to any of the treatments or
  9. Second
  10. Pregnant or breastfeeding women

Frontline chemotherapy randomisation Very High Risk - CT1a Inclusion

  1. Entered in to the FaR-RMS study at diagnosis
  2. Very High Risk disease
  3. Age ≥ 6 months
  4. Available for randomisation ≤60 days after diagnostic /surgery
  5. No prior treatment for RMS other than surgery
  6. Medically fit to receive treatment
  7. Adequate hepatic function :

    a. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the patient is known to have Gilbert's syndrome

  8. Absolute neutrophil count ≥1.0x 109/L (except in patients with documented bone marrow disease)
  9. Platelets ≥ 80 x 109/L (except in patients with documented bone marrow disease)
  10. Fractional Shortening ≥ 28%
  11. Documented negative pregnancy test for female patients of childbearing potential
  12. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  13. Written informed consent from the patient and/or the parent/legal guardian

Exclusion

  1. Active > grade 2 diarrhoea
  2. Prior allo- or autologous Stem Cell Transplant
  3. Uncontrolled inter-current illness or active infection
  4. Pre-existing medical condition precluding treatment
  5. Urinary outflow obstruction that cannot be relieved prior to starting treatment
  6. Active inflammation of the urinary bladder (cystitis)
  7. Known hypersensitivity to any of the treatments or excipients
  8. Second malignancy
  9. Pregnant or breastfeeding women

Frontline chemotherapy randomisation High Risk - CT1b Inclusion

  1. Entered in to the FaR-RMS study at diagnosis
  2. High Risk disease
  3. Age ≥ 6 months
  4. Available for randomisation ≤60 days after diagnostic biopsy/surgery
  5. No prior treatment for RMS other than surgery
  6. Medically fit to receive treatment
  7. Adequate hepatic function :

    a. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, except if the patient is known to have Gilbert's syndrome

  8. Absolute neutrophil count ≥1.0x 109/L
  9. Platelets ≥ 80 x 109/L
  10. Documented negative pregnancy test for female patients of childbearing potential
  11. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  12. Written informed consent from the patient and/or the parent/legal guardian

Exclusion

  1. Active > grade 2 diarrhoea
  2. Prior allo- or autologous Stem Cell Transplant
  3. Uncontrolled inter-current illness or active infection
  4. Pre-existing medical condition precluding treatment
  5. Urinary outflow obstruction that cannot be relieved prior to starting treatment
  6. Active inflammation of the urinary bladder (cystitis)
  7. Known hypersensitivity to any of the treatments or excipients
  8. Second malignancy
  9. Pregnant or breastfeeding women

Frontline Radiotherapy Note: eligible patients may enter multiple radiotherapy randomisations.

Radiotherapy Inclusion - for all radiotherapy randomisations

  1. Entered in to the FaR-RMS study (at diagnosis or prior to radiotherapy randomisation)
  2. Very High Risk, High Risk and Standard Risk disease
  3. ≥ 2 years of age
  4. Receiving frontline induction treatment as part of the FaR-RMS trial or with a IVA/IVADo based chemotherapy regimen patients for whom. Note that patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible
  5. Patient assessed as medically fit to receive the radiotherapy
  6. Documented negative pregnancy test for female patients of childbearing potential
  7. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  8. Written informed consent from the patient and/or the parent/legal guardian

Radiotherapy Exclusion - for all radiotherapy randomisations

  1. Prior allo- or autologous Stem Cell Transplant
  2. Second malignancy
  3. Pregnant or breastfeeding women
  4. Receiving radiotherapy as brachytherapy

RT1a Specific Inclusion

  1. Primary tumour deemed resectable (predicted R0/ R1 resection feasible) after 3 cycles of induction chemotherapy (6 cycles for disease)
  2. radiotherapy required in addition to surgical resection (local decision).
  3. Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease

RT1b Specific Inclusion

  1. Primary tumour deemed resectable (predicted R0/R1 resection) after 3 cycles of induction chemotherapy (6 cycles for metastatic disease).
  2. Adjuvant radiotherapy required in addition to surgical resection (local decision)
  3. Higher Local Failure Risk (HLFR) based on presence of either of the following criteria:

    1. Unfavourable site
    2. Age ≥ 18yrs
  4. Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease

RT1c Specific Inclusion

  1. Primary radiotherapy indicated (local decision)
  2. Higher Local Failure Risk (HLFR) based on either of the following criteria:

    1. Unfavourable site
    2. Age ≥ 18yrs
  3. Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease

RT2

  1. Available for randomisation after cycle 6 and before the start of cycle 9 of induction chemotherapy.
  2. Unfavourable metastatic disease, defined as Modified Oberlin Prognostic Score 2-4

    • Note: Definition of metastatic lesions for RT2 eligibility

Modified Oberlin Prognostic Score (1 point for each adverse factor):

  • Age ≥10y
  • Extremity, Other, Unidentified Primary Site
  • Bone and/ or Bone Marrow involvement
  • ≥3 metastatic sites

Unfavourable metastatic disease: 2- 4 adverse factors Favourable metastatic disease: 0-1 adverse factors

Maintenance chemotherapy (Very High Risk) - CT2a Inclusion Randomisation must take place during the 12th cycle of maintenance chemotherapy.

  1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
  2. Very High Risk disease
  3. Received frontline induction chemotherapy as part of the FaR-RMS trial or with a IVA/IVADo based chemotherapy regimen

    a. Patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible

  4. Completed 11 cycles of VnC maintenance treatment (either oral or IV regimens)
  5. No evidence of progressive disease
  6. Absence of severe vincristine neuropathy - i.e requiring discontinuation of vincristine treatment)
  7. Medically fit to continue to receive treatment
  8. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  9. Written informed consent from the patient and/or the parent/legal guardian

Exclusion

  1. Prior allo- or autologous Stem Cell Transplant
  2. Uncontrolled intercurrent illness or active infection
  3. Urinary outflow obstruction that cannot be relieved prior to starting treatment
  4. Active inflammation of the urinary bladder (cystitis)
  5. Second malignancy
  6. Pregnant or breastfeeding women

Maintenance chemotherapy (High Risk) - CT2b Randomisation must take place during the 6th cycle of maintenance chemotherapy. Inclusion

  1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
  2. High Risk disease
  3. Received frontline induction chemotherapy as part of the FaR-RMS trial or with a IVA based chemotherapy regimen. Note that patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible
  4. Completed 5 cycles of VnC maintenance treatment
  5. No evidence of progressive disease
  6. Absence of severe vincristine neuropathy i.e. requiring discontinuation of vincristine treatment
  7. Medically fit to continue to receive treatment
  8. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  9. Written informed consent from the patient and/or the parent/legal guardian

Exclusion

  1. Prior allo- or autologous Stem Cell Transplant
  2. Uncontrolled inter current illness or active infection
  3. Urinary outflow obstruction that cannot be relieved prior to starting treatment
  4. Active inflammation of the urinary bladder (cystitis)
  5. Second malignancy
  6. Pregnant or breastfeeding women

CT3 Chemotherapy

Inclusion:

  1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
  2. First or subsequent relapse of histologically verified RMS
  3. Age ≥ 6 months
  4. Measurable or evaluable disease
  5. No cytotoxic chemotherapy or other medicinal product (IMP) within previous three weeks: within two weeks for vinorelbine and cyclophosphamide maintenance chemotherapy
  6. Medically fit to receive trial treatment
  7. Documented negative pregnancy test for female patients of childbearing potential within 7 days of planned randomisation
  8. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
  9. Written informed consent from the patient and/or the parent/legal guardian

Exclusion:

  1. Progression during frontline therapy without previous response (=Refractory to treatment)
  2. Prior regorafenib or temozolomide
  3. Active > grade 1 diarrhoea
  4. ALT or AST >3.0 x upper limit normal (ULN)
  5. Bilirubin, Total >1.5 x ULN; total bilirubin is allowed up to 3 x ULN if Gilbert's syndrome is documented
  6. Patients with unstable angina or new onset angina (within 3 months of planned date of randomisation), recent myocardial infarction (within 6 months of randomisation) and those with cardiac failure (NYHA) Classification 2 or higher Cardiac abnormalities such as congestive heart failure (Modified Ross Heart Failure Classification for Children = class 2) and cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted)
  7. Uncontrolled hypertension > 95th centile for age and gender
  8. Prior allo- or autologous Stem Cell Transplant
  9. Uncontrolled inter-current illness or active infection
  10. Pre-existing medical condition precluding treatment
  11. Known hypersensitivity to any of the treatments or excipients
  12. Second malignancy
  13. Pregnant or breastfeeding women
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,672 participants (estimated)

Study arms

  • Experimental
    Phase 1b Dose finding: VHR induction - IRIVA

    Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2. Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9. Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.

    Drug: Irinotecan · Drug: Actinomycin D · Drug: Ifosfamide · Drug: Vincristine

  • Active comparator
    CT1A: VHR induction - IVADO

    Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9. Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4

    Drug: Actinomycin D · Drug: Doxorubicin · Drug: Ifosfamide · Drug: Vincristine

  • Experimental
    CT1A: VHR Induction IRIVA

    Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9. Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.

    Drug: Irinotecan · Drug: Actinomycin D · Drug: Ifosfamide · Drug: Vincristine

  • Active comparator
    CT1B: HR Induction IVA

    Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9. Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.

    Drug: Actinomycin D · Drug: Ifosfamide · Drug: Vincristine

  • Experimental
    CT1B: HR Induction IRIVA

    Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9. Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.

    Drug: Irinotecan · Drug: Actinomycin D · Drug: Ifosfamide · Drug: Vincristine

  • Experimental
    RT1A: Preoperative Radiotherapy

    To be given either 41.4 Gy or 50.4 Gy prior to surgery

    Radiation: radiotherapy

  • Active comparator
    RT1A: Post operative radiotherapy

    To be given either 41.4 Gy or 50.4 Gy following surgery

    Radiation: radiotherapy

  • Experimental
    RT1B: Radiotherapy for resectable disease: dose escalated

    To receive 50.4 Gy

    Radiation: radiotherapy

  • Active comparator
    RT1B: Radiotherapy for resectable disease: standard dose

    To receive 41.4 Gy

    Radiation: radiotherapy

  • Experimental
    RT1C: Radiotherapy for unresectable disease: dose escalated

    To receive 59.4 Gy

    Radiation: radiotherapy

  • Active comparator
    RT1C: Radiotherapy for unresectable disease: standard dose

    To receive 50.4 Gy

    Radiation: radiotherapy

  • Experimental
    RT2: Radiotherapy to primary tumour and involved lymph nodes

    Radiotherapy to the primary tumour and involved regional lymph nodes only

    Radiation: radiotherapy

  • Experimental
    RT2: Radiotherapy to all metastatic sites

    Radiotherapy given to all metastatic sites

    Radiation: radiotherapy

  • Experimental
    CT2A: VHR Maintenance - VC

    Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days

    Drug: Vinorelbine · Drug: Cyclophosphamide

  • No intervention
    CT2A: Maintenance -Stop treatment

    To stop treatment at the point of randomisation

  • Experimental
    CT2B: HR Maintenance - VC

    Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days

    Drug: Vinorelbine · Drug: Cyclophosphamide

  • No intervention
    CT2B: HR Maintenance - Stop Treatment

    To stop treatment at the point of randomisation

  • Active comparator
    CT3: Relpased Chemotherapy - VIRT

    Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 (Escalate to 150mg/m2/day in Cycle 2 if no toxicity \> grade 3) as an oral tablets prior to vincristine and irinotecan on days 1-5

    Drug: Irinotecan · Drug: Vincristine · Drug: Temozolomide

  • Experimental
    CT3: Relapsed Chemotherapy - VIRR

    Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Regorafenib: Children between 6 and 24 months = 65 mg/m2, children less than 12 and/or less than 40kg dose = 82 mg/m2 Maximum 120 mg, Fixed dose of 120 mg for patients over 12 years of age AND ≥ 40 kg, as an oral tablets on days 8 to 21.

    Drug: Irinotecan · Drug: Vincristine · Drug: Regorafenib

Interventions

  • antineoplastic enzyme inhibitor

  • DrugDactinomycinStudies of DactinomycinDactinomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Antineoplastic agent that is a polypeptide antibiotic

    Also known as: Dactinomycin

  • An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius

  • chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

  • anti neoplastic vinca alkaloid agent

  • vinca alkaloid with a role as an antineoplastic agent

  • Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent

  • oral antineoplastic alkylating agent

  • Radiationradiotherapy

    Ionising radiation

  • Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).

06

What researchers measure

Primary outcomes

  1. Event Free Survival (RT2)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From randomisation to first failure event, timeframe 36 months

  2. Event Free Survival (CT1A)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From randomisation to first failure event, timeframe 36 months

  3. Event Free Survival (CT1B)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From randomisation to first failure event, timeframe 36 months

  4. Event Free Survival (CT2A)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From randomisation to first failure event, timeframe 36 months

  5. Event Free Survival (CT2B)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: Time from randomisation to first failure event, timeframe 36 months

  6. Event Free Survival (CT3)

    To determine whether new systemic therapy regimens improve event free survival in relapsed RMS compared to standard therapy (VIRT) (CT3): Initial new systemic therapy combination to be tested: o Regorafenib (R) added to vincristine and irinotecan (VIR) (VIRR)

    Time frame: Patients will be followed up for a minimum of 6 years from trial entry (or 5 years from end of relapsed trial treatment, whichever comes later). Patients will be followed up for progression and death until the end of trial definition has been met.

  7. Local Failure Free Survival (RT1A and RT1B)

    A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure

    Time frame: Time from randomisation to first local failure event, timeframe 36 months

  8. Local Failure Free Survival (RT1C)

    A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure

    Time frame: Time from randomisation to first local failure event, timeframe 36 months

Secondary outcomes

  1. Recommended Phase II Dose (Phase 1b)

    Based on tolerability, where tolerability is evaluated through the occurrence of dose limiting toxicity (DLT).

    Time frame: From first patient first visit in dose finding study until appropriate dose level found, estimated 9 months

  2. Maximum Tolerated Dose (Phase 1b)

    Dose level at which no or one participant experiences a DLT when at least two of three to six participants experience a DLT at the next highest dose.

    Time frame: From first patient first visit in dose finding study until appropriate dose level

  3. Toxicity (All chemotherapy randomisations)

    Categorised and graded using Common Terminology Criteria for Adverse Events

    Time frame: From date of protocol defined treatment until 30 days after the administration of the last treatment

  4. Dose Limiting Toxicity (Phase 1b)

    Diarrhoea: Grade 3 for \>3 days despite loperamide therapy Diarrhoea: Grade 4 despite loperamide therapy. Enterocolitis: Grade 3 or above Ileus: Grade 3 or above for more than 3 days Oral mucositis: Grade 3 above for \>3 days despite optimal supportive care Persistent neutropenia or thrombocytopenia leading to delay of start of next course by \>7 days; i.e. starting \> day 28 Any grade 3 or 4 toxicity resulting in discontinuation of the new combination Any grade 5 toxicity

    Time frame: From commencement of treatment until 21 days after the start of cycle 2 (each cycle is 21 days)

  5. Response (Phase 1b, CT1A, CT1B)

    defined as complete (CR) or partial response (PR) and is clinically defined. Patients who are not assessable for response - e.g. because of early stopping of treatment or death - will be assumed to be non-responders.

    Time frame: Response assessed after course 3 (63 days) and 6 (126 days)

  6. Tolerability (CT3)

    To determine the tolerability of the regimens.

    Time frame: From registration/randomisation until death/study endpoint

  7. Overall Survival (CT1A)

    Death from any cause

    Time frame: From randomisation to death from any cause, assessed for 36 months

  8. Overall Survival (CT1B)

    Death from any cause

    Time frame: From randomisation to death from any cause, assessed for 36 months

  9. Overall Survival (CT2A)

    Death from any cause

    Time frame: From randomisation to death from any cause, assessed for 36 months

  10. Overall Survival (CT2B)

    Death from any cause

    Time frame: From randomisation to death from any cause, assessed for 36 months

  11. Overall Survival (RT1A and RT1B)

    Death from any cause

    Time frame: From randomisation to death from any cause, assessed for 36 months

  12. Overall Survival (RT1C)

    Death from any cause

    Time frame: From RT1C randomisation to death from any cause, assessed for 36 months

  13. Overall Survival (RT2)

    Death from any cause

    Time frame: From RT2 randomisation to death from any cause, as assessed for 36 months

  14. Overall Survival (CT3)

    To evaluate the anti-tumour activity and effect on overall survival of VIRR when compared to standard therapy

    Time frame: Patients will be followed up for a minimum of 6 years from trial entry (or 5 years from end of relapsed trial treatment, whichever comes later). Patients will be followed up for progression and death until the end of trial definition has been met.

  15. Overall Survival (all patients)

    Death from any cause

    Time frame: From randomisation/registration to death from any cause, assessed for 36 months

  16. Acute wound complications and post-operative complications (RT1A and RT1B)

    specific grade 3 and above complications according to CTCAE v 4 and Clavien Dindo scale. Specific wound complications within the same time frame will also be collected

    Time frame: Within 120 days from surgery

  17. Acute post-radiotherapy complications (All radiotherapy randomisations)

    any grade 3 and above event according to CTCAE v 4

    Time frame: Within 120 days from start of radiotherapy

  18. Late complications (RT1A, RT1B. RT1C)

    specific grade 3 and above events according to CTCAE and Clavien-Dindo scale

    Time frame: After 120 days from last local therapy

  19. Loco-regional failure-free survival (All radiotherapy randomisations)

    A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior concurrent local, regional or distant failure. A regional event is relapse or progression of tumour at regional lymph nodes at any time even if there has been a prior distant failure.

    Time frame: From randomisation to first local and/or regional failure event, assessed for 36 months

  20. Health related quality of life (RT1A and RT2) self-reported questionnaire completed by patient

    will be assessed using Pediatric quality of life questionnaire (PedsQL) for the paediatric population (under 18 years). The minimum score is 0 where quality of life is completely unaffected by the intervention to 4 where quality of life is severely affected.

    Time frame: 4 timepoints: 1) 1 day of start of radiotherapy, 2) at completion of radiotherapy, average 5 weeks after start of radiotherapy, 3) 3 months and 4) 24 months following radiotherapy

  21. Health related quality of life (RT1A and RT2) self-reported questionnaire completed by the patient

    will be assessed using European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire 30 (EORTC QLQ-C30) for patients 18 years of age and over. The minimum score is 0 where quality of life is completely unaffected by the intervention to 4 where quality of life is severely affected.

    Time frame: 4 timepoints: 1) 1 day of start of radiotherapy, 2) at completion of radiotherapy, average 5 weeks after start of radiotherapy, 3) 3 months and 4) 24 months following radiotherapy

  22. Health related quality of life (CT3) self-reported questionnaire completed by the patient

    will be assessed using Pediatric quality of life questionnaire (PedsQL) for the paediatric population (under 18 years). The minimum score is 0 where quality of life is completely unaffected by the intervention to 4 where quality of life is severely affected.

    Time frame: 3 timepoints: Each Cycle is 28 days. Timepoint 1: Day 0 of cycle 1 (prior to starting treatment), Timepoint 2 day 0 cycle 3, Timepoint 3) day 0 cycle 5

  23. Health related quality of life (CT3) self-reported questionnaire completed by the patient

    will be assessed using European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire 30 (EORTC QLQ-C30) for patients 18 years of age and over. The minimum score is 0 where quality of life is completely unaffected by the intervention to 4 where quality of life is severely affected.

    Time frame: 3 timepoints: Each Cycle is 28 days. Timepoint 1: Day 0 of cycle 1 (prior to starting treatment), Timepoint 2 day 0 cycle 3, Timepoint 3) day 0 cycle 5

  24. Acceptability and Palatability of Regorafenib (CT3)

    "Acceptability and Palatability Questionnaire" To evaluate the acceptability and palatability of regorafenib formulations

    Time frame: 1 timepoint: Day 8 of cycle 1 (Each Cycle is 28 days)

  25. PET Response (if participating in PET Sub-study)

    assessed by PERCIST criteria and visual 'Deauville like' criteria

    Time frame: After three cycles of chemotherapy (each cycle is 21 days)

  26. Event Free Survival (all patients)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From date of randomisation/registration to death from any cause, assessed for 36 months

  27. Event Free Survival (if participating in PET Sub-study)

    Failure events are: * Relapse or progression of existing disease, or occurrence of disease at new sites, * Death from any cause without disease progression, * Second malignant neoplasm

    Time frame: From date of randomisation/registration to death from any cause, assessed for 36 months

  28. Local Failure Free Survival (if participating in PET Sub-study)

    A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure

    Time frame: From date of randomisation/registration to first local failure event, assessed for 36 months

07

Study locations

120 of 128 sites recruiting
  • Queensland Children's Hospital
    Brisbane, 4101, Australia
    Recruiting
    • R Walker · Contact
  • Chris O'brien Lifehouse
    Camperdown, Australia
    Recruiting
    • Angela Hong · Contact
  • Monash Children's Hospital
    Clayton, Australia
    Recruiting
    • Paul Wood · Contact
  • Peter Maccallum Cancer Centre
    Melbourne, Australia
    Recruiting
    • Jeremy Lewin · Contact
  • Royal Childrens Hospital Melbourne
    Melbourne, Australia
    Recruiting
    • Marty Campbell · Contact
  • John Hunter Children's Hospital
    New Lambton Heights, 2310, Australia
    Recruiting
    • E Hesketh · Contact
  • Perth Children's Hospital
    Perth, Australia
    Recruiting
    • Marianne Phillips · Contact
  • Sydney Children's Hospital
    Sydney, Australia
    Recruiting
    • Timothy Trahair · Contact
  • The Childrens Hospital At Westmead
    Sydney, Australia
    Recruiting
    • Jessica Ryan · Contact
  • Westmead Hospital
    Westmead, Australia
    Recruiting
    • Jennifer Chard · Contact
  • Princess Alexandra Hospital
    Woolloongabba, Australia
    Recruiting
    • Rick Walker · Contact
  • Kepler University Clinic Linz
    Linz, Austria
    Recruiting
    • B Aistleitner · Contact
    • B Aistleitner · Principal investigator
  • St Anna Childrens Hospital
    Vienna, Austria
    Recruiting
    • Ruth Ladenstein · Contact
  • Hopital Universitaire Des Enfants Reine Fabiola
    Brussels, Belgium
    Recruiting
    • Christine Devalck · Contact
  • Cliniques Universitaires Saint Luc
    Bruxelles, Belgium
    Recruiting
    • B Brichard · Contact
  • Universitair Ziekenhuis Gent
    Gent, Belgium
    Recruiting
    • C Dhooge · Contact
  • Uz Leuven Campus Gasthuisberg
    Leuven, Belgium
    Recruiting
    • M Renard · Contact
  • Centre Hospitalier Regional De La Citadelle
    Liège, Belgium
    Recruiting
    • S Gatineau-Sailliant · Contact
  • Clinique Chc Montlegia
    Liège, Belgium
    Recruiting
    • L Roufiange · Contact
  • Masaryk University Hospital Brno
    Brno, 625 00, Czechia
    Recruiting
    • Peter Mudry · Contact
  • Aarhus University Hospital
    Aarhus, Denmark
    Recruiting
    • Pernille Wendtland · Contact
  • University Hospital Rigshospitalet
    Copenhagen, Denmark
    Recruiting
    • Lisa Hjalgrim · Contact
  • Centre Hospitalier Universitaire D'angers
    Angers, France
    Recruiting
    • S Proust · Contact
  • Centre Hospitalier Regional Universitaire Besancon - Hopital Jean Minjoz
    Besançon, France
    Recruiting
    • S Klein · Contact
  • Centre Hospitalier Universitaire De Bordeaux - Hopital Pellegrin
    Bordeaux, France
    Recruiting
    • C Verite · Contact
  • Centre Hospitalier Regional Universitaire Brest - Hopital Morvan
    Brest, France
    Recruiting
    • L Carausu · Contact
  • Centre Francois Baclesse
    Caen, France
    Recruiting
    • F Missohou · Contact
  • Centre Hospitalier Universitaire De Caen
    Caen, France
    Recruiting
    • D Bodet · Contact
  • Centre Hospitalier Universitaire Dijon Bourgogne - Hopital D'enfants
    Dijon, France
    Recruiting
    • C Briandet · Contact
  • Centre Hospitalier Universitaire De Grenoble
    Grenoble, France
    Recruiting
    • D Plantaz · Contact
  • Centre Hospitalier Universitaire La Reunion
    La Réunion, France
    Recruiting
    • Y Reguerre · Contact
  • Centre Oscar Lambret
    Lille, France
    Recruiting
    • A Defachelles · Contact
  • Centre Leon Berard
    Lyon, France
    Recruiting
    • N Corradini · Contact
  • Hopital De La Timone (ap-hm)
    Marseille, France
    Recruiting
    • A Rome · Contact
  • Centre Hospitalier Universitaire De Nancy
    Nancy, France
    Recruiting
    • L Mansuy · Contact
  • Centre Hospitalier Universitaire De Nantes
    Nantes, France
    Recruiting
    • M Cleirec · Contact
  • Hopital Armand Trousseau
    Paris, France
    Recruiting
    • H Boutroux · Contact
  • Institut Curie
    Paris, France
    Recruiting
    • D Orbach · Contact
  • Centre Hospitalier Universitaire Haut Levque
    Pessac, France
    Recruiting
    • A Huchet · Contact
  • Centre Hospitalier Universitaire De Poitiers
    Poitiers, France
    Recruiting
    • F Millot · Contact
  • Chu De Reims
    Reims, France
    Recruiting
    • C Pluchart · Contact
  • Centre Eugne Marquis De Rennes
    Rennes, France
    Recruiting
    • J Leseur · Contact
  • Centre Hospitalier Universitaire De Rennes - Hopital Pontchaillou
    Rennes, France
    Recruiting
    • S Taque · Contact
  • Centre Hospitalier Universitaire De Rouen
    Rouen, France
    Recruiting
    • A Marie Cardine · Contact
  • Centre Hospitalier Universitaire Saint-etienne
    Saint-Étienne, France
    Recruiting
    • C Berger · Contact
  • Strasbourg Hautepierre
    Strasbourg, France
    Recruiting
    • S Jannier · Contact
  • Centre Hospitalier Universitaire De Toulouse - Hopital Des Enfants
    Toulouse, France
    Recruiting
    • MP Castex · Contact
  • Centre Hospitalier Regional Universitaire De Tours - Hopital Clocheville
    Tours, France
    Recruiting
    • J Serre · Contact
  • Gustave Roussy
    Villejuif, 94805, France
    Recruiting
    • Veronique Minard-Colin · Contact
  • Children's General Hospital P and A Kyriakou
    Athens, 115 27, Greece
    Recruiting
    • Marina Servitzoglou · Contact
  • Department of Pediatric Hematology-oncology - Aghia Sophia Children's Hospital
    Athens, Greece
    Recruiting
    • Vasiliki Tzotzola · Contact
  • Hellenic Society of Pediatric Hematology- Oncology
    Athens, Greece
    Recruiting
    • Apostolos Pourtsidis · Contact
  • University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia
    Athens, Greece
    Recruiting
    • Antonis Kattamis · Contact
  • Children's and Adolescent's Oncology Clinic, "MITERA" Children's Hospital
    Attikí, 151 23, Greece
    Recruiting
    • Apostolos Pourtsidis · Contact
  • Hematology-oncology Children's Clinic, University General Hospital of Heraklion
    Iraklio, 715 00, Greece
    Recruiting
    • Nikolaos Katzilakis · Contact
  • Ippokratio General Hospital of Thessaloniki
    Thessaloniki, Greece
    Recruiting
    • Evgenia Papakonstantinou · Contact
  • Ahepa University General Hospital of Thessaloniki
    Thessaloníki, Greece
    Recruiting
    • Emmanouil Chatzipantelis · Contact
  • Our Lady's Children's Hospital
    Crumlin, Ireland
    Not yet recruiting
    • Cormac Owens · Contact
  • Rambam Health Care Campus
    Haifa, Israel
    Recruiting
    • Shifra Ash · Contact
  • Hadassah University Medical Centre
    Jerusalem, Israel
    Recruiting
    • Dror Raviv · Contact
  • Schneider Medical Centre
    Petah Tikva, Israel
    Recruiting
    • Shira Amar · Contact
  • Dana Children's Hospital, Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel
    Recruiting
    • Dror Levin · Contact
  • Chaim Sheba Medical Centre
    Tel HaShomer, Israel
    Recruiting
    • Iris Kvenstel · Contact
  • University Hospital of Padova (azienda Ospedaliera of Padua)
    Padova, Italy
    Not yet recruiting
    • Gianni Bisogno · Contact
  • University Medical Centre Groningen
    Groningen, Netherlands
    Recruiting
    • Wim Tissing · Contact
  • Prinses Maxima Centrum Voor Kinderoncologie
    Utrecht, Netherlands
    Recruiting
    • Hans Merks · Contact
  • Starship Children's Health
    Auckland, New Zealand
    Recruiting
    • Mandy De Silva · Contact
  • Christchurch Hospital
    Christchurch, New Zealand
    Recruiting
    • Tristan Pettitt · Contact
  • Haukeland University Hospital - Paediatric
    Bergen, Norway
    Recruiting
    • Ingrid Kristin Torsvik · Contact
  • Oslo University Hospital - Paediatrics
    Oslo, Norway
    Recruiting
    • Heidi Glosli · Contact
  • Oslo University Hospital - Radiumhospitalet
    Oslo, Norway
    Recruiting
    • Kjetil Boye · Contact
  • University Hospital of North Norway - Paediatric
    Tromso, Norway
    Recruiting
    • Tove Anita Nystad · Contact
  • St Olavs Hospital - Paediatric
    Trondheim, Norway
    Recruiting
    • Bendik Lund · Contact
  • Instituto Portugues De Oncologia De Losbona Francisco Gentil, Epe
    Lisbon, Portugal
    Not yet recruiting
    • Cristina Mendes · Contact
  • Bratislava, National Institute for Children's Diseases
    Bratislava, Slovakia
    Not yet recruiting
    • Martina Mileskova · Contact
  • University Childrens Hospital Ljubljana
    Ljubljana, Slovenia
    Recruiting
    • Maja Cesen Mazic · Contact
  • University Medical Centre Ljubjlana
    Ljubljana, Slovenia
    Recruiting
    • Cesen Mazic · Contact
  • Hospital Sant Joan De Deu
    Barcelona, Spain
    Recruiting
    • Moira Garraus Oneca · Contact
  • Hospital Universitari Vall D'hebron
    Barcelona, Spain
    Recruiting
    • Raquel Hladun Alvaro · Contact
  • Hospital De Cruces
    Bilbao, 48903, Spain
    Recruiting
    • Ricardo Lopez Almaraz · Contact
  • Hospital Del Nino Jesus
    Madrid, 28009, Spain
    Recruiting
    • David Ruano · Contact
  • Hospital Universitario Gregorio Maranon
    Madrid, 28009, Spain
    Recruiting
    • Cristina Mata · Contact
  • Hospital Universitario La Paz
    Madrid, Spain
    Recruiting
    • Pedro Rubio · Contact
  • Hospital Regional Universitario De Malaga
    Malaga, Spain
    Recruiting
    • Guiomar Gutierrez Schiaffino · Contact
  • Hospital Virgen Del Rocio
    Seville, Spain
    Recruiting
    • Gema Ramirez Villar · Contact
  • Hospital Politecnico U La Fe
    Valencia, 46026, Spain
    Recruiting
    • Antonio Juan Ribelles · Contact
  • Hospital Universitario Miguel Servet Materno - infantil
    Zaragoza, Spain
    Recruiting
    • Ascensión Muñoz · Contact
  • Uppsala University Childrens Hospital
    Uppsala, Sweden
    Recruiting
    • G Ljungman · Contact
  • Kantonsspital Aarau
    Aarau, Switzerland
    Recruiting
    • Andreas Klein-Franke · Contact
  • Universitats-kinderspital Bieder Basel (UKBB)
    Basel, Switzerland
    Recruiting
    • Nicolas von der Weld · Contact
  • Ospedale San Giovanni
    Bellinzona, Switzerland
    Recruiting
    • Pierluigi Brazzola · Contact
  • Inselspital Bern
    Bern, Switzerland
    Recruiting
    • Jochen Roessler · Contact
  • Hug Hopitaux Universitaires De Geneve
    Geneva, Switzerland
    Recruiting
    • Andre Von Buren · Contact
  • Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
    Lausanne, Switzerland
    Recruiting
    • Manuel Diezi · Contact
  • Luzerner Kantonspital - Kinderspital Luzern
    Luzern, Switzerland
    Recruiting
    • Freimut Schilling · Contact
  • Ostschweizer Kinderspital
    St Gallen, Switzerland
    Recruiting
    • Jeanette Greiner · Contact
  • Universitaetsspital Zurich
    Zurich, Switzerland
    Recruiting
    • Willemijn Breunis · Contact
  • Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
    Recruiting
    • Julia Chisholm · Contact020 8642 6011
  • Royal Aberdeen Children's Hospital
    Aberdeen, United Kingdom
    Recruiting
    • Hugh Bishop · Contact
  • Belfast City Hospital
    Belfast, United Kingdom
    Not yet recruiting
    • Robert Johnston · Contact

Showing the first 100 of 128 sites across 20 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Jun 2030, 117 months after the start.

Of 21 phase 1/2 interventional studies under Rhabdomyosarcoma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 65. This study's planned 117 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Nov 12, 2020
StartActual
Sep 17, 2020
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04625907
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Sep 17, 2020
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
May 23, 2024

Study contacts

Bridget Shaw
Contact
farrms@trials.bham.ac.uk
0121 414 2996
Emma Gray
Contact
farrms@trials.bham.ac.uk
0121 414 3799
Meriel Jenney
principal investigator · Chief Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Dactinomycin · Ifosfamide · Vincristine · Vinorelbine · Cyclophosphamide · Regorafenib

Start the discussion